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pTATE-OF-THE-ART PAPER2019The Impact of Bleeding on PCI Outcomesrendan J. Doyle, Charanjit S. Rihal, Dennis A. Gastineau, David R. Holmes, Jr
ore powerful antiplatelet agents reduce the rate of ischemic complications of percutaneous
oronary intervention (PCI) but may increase the risk of bleeding. Doyle and colleagues start
y reviewing several studies where mortality was higher than expected in PCI patients who
uffered bleeding complications. In this review, the basis for a possible causal link between
ost-PCI bleeding and mortality is examined. This risk may be related to blood transfusion,
nd the biological basis for this is reviewed. Further study is recommended for methods to
oth prevent bleeding and reduce the harm associated with transfusion.CLINICAL RESEARCH LINICAL TRIAL
2028isappointing Effect on CIMT for Both
Ramipril and Rosiglitazone in Pre-Diabetic PatientsEditorial Comment
Juan Carlos Kaski,va M. Lonn, Hertzel C. Gerstein, Patrick Sheridan, Sandra Smith, Rafael Diaz, Viswanathan Mohan,
ackie Bosch, Salim Yusuf, Gilles R. Dagenais, MD, for the DREAM (Diabetes REduction Assessment with
amipril and rosiglitazone Medication) and STARR Investigators
he effects of angiotensin-converting enzyme inhibitors and thiazolidinediones on the
natomic progression of vascular disease have not been studied in people with pre-diabetes.
he STARR study randomized almost 1,500 subjects with impaired fasting glucose or
mpaired glucose tolerance to either ramipril or rosiglitazone in a 2  2 factorial design. The
rimary end point of the study was the annualized change of the maximum carotid intima-
edia thickness (CIMT). There was no effect seen for ramipril. There was a nonsignificant
eduction with rosiglitazone, but a significant decrease in the secondary end point that
easured CIMT using a different method. In people with pre-diabetes, treatment with
amipril had a neutral effect on CIMT, while rosiglitazone modestly reduced CIMT
rogression.(continued on page A-25)
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sLINICAL TRIAL2039MRI Protocol Can Measure Atherosclerotic InflammationEditorial Comment
Zahi A. Fayad, Louai Razzouk,
Karen C. Briley-Saebo,jun Y. Tang, Simon P. S. Howarth, Sam R. Miller, Martin J. Graves, Andrew J. Patterson,
ean-Marie U-King-Im, Zhi Y. Li, Stewart R. Walsh, Andrew P. Brown, Peter J. Kirkpatrick,
lizabeth A. Warburton, Paul D. Hayes, Kevin Varty, Jonathan R. Boyle, Michael E. Gaunt,
ndrew Zalewski, Jonathan H. Gillard
reliminary studies indicate that ultrasmall superparamagnetic iron oxide (USPIO)-enhanced
agnetic resonance imaging (MRI) can identify macrophage infiltration in atherosclerotic
laques and may be a surrogate marker of plaque inflammation. Tang and colleagues
andomized 47 patients with carotid stenosis and baseline inflammation to either 10 or 80 mg
f atorvastatin. High-dose atorvastatin produced a highly significant reduction from baseline
n signal intensity, while there was no change with the low dose. Aggressive lipid lowering
ith atorvastatin may produce significant reductions in atherosclerotic inflammation that can
e quantified with USPIO-enhanced MRI.NTERVENTIONAL CARDIOLOGY2053Frequency and Complications of Coronary Aneurysms After DESPatient # 5ti t  ernando Alfonso, Maria-José Pérez-Vizcayno, Miguel Ruiz, Alfonso Sua´rez, Miguel Cazares,
osana Herna´ndez, Javier Escaned, Camino Bañuelos, Pilar Jiménez-Quevedo, Carlos Macaya
lfonso and colleagues reviewed follow-up angiograms from almost 1,200 patients with
revious drug-eluting stent (DES) implantation to identify patients developing coronary
neurysms (CANs). CAN was defined as a localized angiographic dilation of the vessel lumen
t late angiography that was not present immediately after the procedure and that was not
aused by a dissection or contained perforation. Fifteen patients (1.25%) developed CANs.
he 1-year event-free survival was only 49% and was related to CAN size on intravascular
ltrasound (IVUS). In 2 patients, CANs disappeared at repeated late angiography, and IVUS
emonstrated abluminal CAN thrombosis. After DES implantation, CAN may develop and
ay increase the risk of stent thrombosis.ARDIOVASCULAR RISK2061Novel Method for Measuring Arginine Bioavailability Confirms Link to CADEditorial Comment. H. Wilson Tang, Zeneng Wang, Leslie Cho, Danielle M. Brennan, Stanley L. Hazen
itric oxide (NO) is synthesized from arginine in a multistep reaction. Tang and colleagues
ypothesized that the “bioavailability” of arginine may limit the production of NO. They
eveloped a “global arginine bioavailability ratio” (GABR), which measures both arginine and
ts major catabolic products (ornithine and citrulline). GABR was calculated in over 1,000
atients undergoing elective angiography. After adjustment for cardiac risk factors, low
ABR levels predicted both the prevalence of coronary artery disease (CAD) and 3-year risk
f major adverse cardiovascular events. Arginine levels were not predictive. These results
uggest that GABR is a comprehensive measure of reduced NO synthetic capacity.(continued on page A-29)
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wEART FAILURE2070Adiponectin Secretion Enhanced by Natriuretic PeptidesEditorial Comment
Lisa C. Costello-Boerrigter,samu Tsukamoto, Masashi Fujita, Mahoto Kato, Satoru Yamazaki, Yoshihiro Asano, Akiko Ogai,
idetoshi Okazaki, Mitsutoshi Asai, Yoko Nagamachi, Norikazu Maeda, Yasunori Shintani,
etsuo Minamino, Masanori Asakura, Ichiro Kishimoto, Tohru Funahashi, Hitonobu Tomoike,
asafumi Kitakaze
diponectin is a cytokine derived from adipose tissue that may be cardioprotective.
sukamoto and colleagues investigated the correlation between adiponectin and the
atriuretic peptides. Both atrial natriuretic peptide (ANP) and brain natriuretic peptide
ncreased the expression and secretion of adiponectin from adipocytes grown in culture.
hirty patients with CHF were then randomized to a 4-day infusion of ANP or placebo.
NP infusion increased circulating adiponectin levels. Natriuretic peptides enhance
diponectin production by human adipocytes in vitro and in vivo.YEAR IN CARDIOLOGY SERIES EAR IN CARDIOLOGY SERIES2080The Year in Interventional Cardiologyimon R. Dixon, Cindy L. Grines, William W. O’Neill
ixon and colleagues provide readers with a review of major scientific work published in the
eld of interventional cardiology in 2008, including late-breaking trials presented at several
onferences. This paper provides a broad overview of the field for general cardiologists, as well
s a framework for more detailed study for those with a specific interest in interventional
ardiology. Some of the highlights include synopses and commentary for controversial issues
ncluding the risk of stent thrombosis, periprocedural anticoagulation, and surgical compared
ith percutaneous revascularization.
